Funded Biomarker Testing
69 items
Testing on all sinonasal carcinoma where HPV and EBV have been excluded
Funded Biomarker Disease Site: Head and Neck
Biomarker: SMARCA4, SMARCB1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hospital for Sick Children (SickKids), William Osler Health System
Testing on all sinonasal carcinoma where HPV and EBV have been excluded, and with retained/equivocal SMARC immunohistochemistry test results.
Funded Biomarker Disease Site: Head and Neck
Biomarker: DEK-AFF2, EWSR1-FLI, EGFR, IDH2, NUTM1, PAX3, PAX7
Testing Method:Sequencing
Testing Site: Hospital for Sick Children (SickKids), University Health Network
Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.
Funded Biomarker Disease Site: Lung
Biomarker: Acquired EGFR T790M
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered
Funded Biomarker Disease Site: Hepatobiliary
Biomarker: FGFR2
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Testing on previously untreated CLL/SLL patients once therapy is being considered.
Funded Biomarker Disease Site: Hematology
Biomarker: Chromosome 17p Deletion or TP53 Mutation or Unmutated Immunoglobulin Heavy Chain Variable Region (IgHV)
Testing Method:N/A
Testing Site: Health Sciences North, University Health Network
Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma).
Funded Biomarker Disease Site: Head and Neck
Biomarker: EBER
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Testing to support diagnosis of sex-cord stromal tumours.
Funded Biomarker Disease Site: Ovary
Biomarker: DICER1, FOXL2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network
Testing to support newly diagnosed adult cases of Ependymoma (spinal cord).
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: MYCN Amplification
Testing Method:Fluoroscence In Situ Hybridization (FISH), Single Nucleotide Polymorphism (SNP) Array
Testing Site: London Health Sciences Centre, Trillium Health Partners
TP53 testing should be performed on patients with an abnormal p53.
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: TP53 SNV
Testing Method:Sequencing
Testing Site: Hospital for Sick Children (SickKids)